Literature DB >> 28062252

Using neuroimaging to individualize TMS treatment for depression: Toward a new paradigm for imaging-guided intervention.

Bruce M Luber1, Simon Davis2, Elisabeth Bernhardt2, Andrada Neacsiu3, Lori Kwapil2, Sarah H Lisanby4, Timothy J Strauman2.   

Abstract

The standard clinical technique for using repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder (MDD) is associated with limited efficacy to date. Such limited efficacy may be due to reliance on scalp-based targeting rather than state-of-the-science methods which incorporate fMRI-guided neuronavigation based on a specific model of neurocircuit dysfunction. In this review, we examine such a specific model drawn from regulatory focus theory, which postulates two brain/behavior systems, the promotion and prevention systems, underlying goal pursuit. Individual differences in these systems have been shown to predict vulnerability to MDD as well as to comorbid generalized anxiety disorder (GAD). Activation of an individual's promotion or prevention goals via priming leads to motivational and affective responses modulated by the individual's appraisal of their progress in attaining the goal. In addition, priming promotion vs. prevention goals induces discriminable patterns of brain activation that are sensitive to the effects of depression and anxiety: MDD is associated with promotion system failure, anhedonic/dysphoric symptoms, and hypoactivation in specific regions in left prefrontal cortex, whereas GAD is associated with prevention system failure, hypervigilant/agitated symptoms, and hyperactivation in right prefrontal cortex (PFC). These left and right PFC locations can be directly targeted in an individualized manner for TMS. Additionally, this individually targeted rTMS can be integrated with cognitive interventions designed to activate the neural circuitry associated with promotion vs. prevention, thus allowing the neuroplasticity induced by the rTMS to benefit the systems likely to be involved in remediating depression. Targeted engagement of cortical systems involved in emotion regulation using individualized fMRI guidance may help increase the efficacy of rTMS in depression. Published by Elsevier Inc.

Entities:  

Keywords:  Depression; Multimodal therapy; Prevention; Promotion; Regulatory focus; TMS; Translation; fMRI

Mesh:

Year:  2017        PMID: 28062252      PMCID: PMC5344760          DOI: 10.1016/j.neuroimage.2016.12.083

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  52 in total

Review 1.  An integrative theory of prefrontal cortex function.

Authors:  E K Miller; J D Cohen
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

Review 2.  Neurobiology of the structure of personality: dopamine, facilitation of incentive motivation, and extraversion.

Authors:  R A Depue; P F Collins
Journal:  Behav Brain Sci       Date:  1999-06       Impact factor: 12.579

3.  Frequency dependence of antidepressant response to left prefrontal repetitive transcranial magnetic stimulation (rTMS) as a function of baseline cerebral glucose metabolism.

Authors:  T A Kimbrell; J T Little; R T Dunn; M A Frye; B D Greenberg; E M Wassermann; J D Repella; A L Danielson; M W Willis; B E Benson; A M Speer; E Osuch; M S George; R M Post
Journal:  Biol Psychiatry       Date:  1999-12-15       Impact factor: 13.382

4.  The amygdala response to emotional stimuli: a comparison of faces and scenes.

Authors:  Ahmad R Hariri; Alessandro Tessitore; Venkata S Mattay; Francesco Fera; Daniel R Weinberger
Journal:  Neuroimage       Date:  2002-09       Impact factor: 6.556

5.  Combination of 5 Hz repetitive transcranial magnetic stimulation (rTMS) and tactile coactivation boosts tactile discrimination in humans.

Authors:  Patrick Ragert; Hubert R Dinse; Burkhard Pleger; Claudia Wilimzig; Elke Frombach; Peter Schwenkreis; Martin Tegenthoff
Journal:  Neurosci Lett       Date:  2003-09-11       Impact factor: 3.046

6.  Adaptive self-regulation of unattainable goals: goal disengagement, goal reengagement, and subjective well-being.

Authors:  Carsten Wrosch; Michael F Scheier; Gregory E Miller; Richard Schulz; Charles S Carver
Journal:  Pers Soc Psychol Bull       Date:  2003-12

Review 7.  Anterior prefrontal cortex: insights into function from anatomy and neuroimaging.

Authors:  Narender Ramnani; Adrian M Owen
Journal:  Nat Rev Neurosci       Date:  2004-03       Impact factor: 34.870

8.  Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression: a double-blind controlled study.

Authors:  E Klein; I Kreinin; A Chistyakov; D Koren; L Mecz; S Marmur; D Ben-Shachar; M Feinsod
Journal:  Arch Gen Psychiatry       Date:  1999-04

9.  Neural signals for the detection of unintentional race bias.

Authors:  David M Amodio; Eddie Harmon-Jones; Patricia G Devine; John J Curtin; Sigan L Hartley; Alison E Covert
Journal:  Psychol Sci       Date:  2004-02

10.  Cortical midline structures and the self.

Authors:  Georg Northoff; Felix Bermpohl
Journal:  Trends Cogn Sci       Date:  2004-03       Impact factor: 20.229

View more
  25 in total

1.  A pilot study of GABAB correlates with resting-state functional connectivity in five depressed female adolescents.

Authors:  Irena Balzekas; Charles P Lewis; Julia Shekunov; John D Port; Gregory A Worrell; Hang Joon Jo; Paul E Croarkin
Journal:  Psychiatry Res Neuroimaging       Date:  2018-05-31       Impact factor: 2.376

2.  On the Concurrent Use of Self-System Therapy and Functional Magnetic Resonance Imaging-Guided Transcranial Magnetic Stimulation as Treatment for Depression.

Authors:  Andrada D Neacsiu; Bruce M Luber; Simon W Davis; Elisabeth Bernhardt; Timothy J Strauman; Sarah H Lisanby
Journal:  J ECT       Date:  2018-12       Impact factor: 3.635

Review 3.  Rehabilitating the addicted brain with transcranial magnetic stimulation.

Authors:  Marco Diana; Tommi Raij; Miriam Melis; Aapo Nummenmaa; Lorenzo Leggio; Antonello Bonci
Journal:  Nat Rev Neurosci       Date:  2017-09-29       Impact factor: 34.870

4.  Unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant late-life depression.

Authors:  Alisson Paulino Trevizol; Kyle W Goldberger; Benoit H Mulsant; Tarek K Rajji; Jonathan Downar; Zafiris J Daskalakis; Daniel M Blumberger
Journal:  Int J Geriatr Psychiatry       Date:  2019-04-08       Impact factor: 3.485

5.  A novel low-cost approach for navigated transcranial magnetic stimulation.

Authors:  Jakob Rodseth; Edward P Washabaugh; Chandramouli Krishnan
Journal:  Restor Neurol Neurosci       Date:  2017       Impact factor: 2.406

Review 6.  Device-Based Modulation of Neurocircuits as a Therapeutic for Psychiatric Disorders.

Authors:  Zhi-De Deng; Bruce Luber; Nicholas L Balderston; Melbaliz Velez Afanador; Michelle M Noh; Jeena Thomas; William C Altekruse; Shannon L Exley; Shriya Awasthi; Sarah H Lisanby
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-01-06       Impact factor: 13.820

Review 7.  Defining Individual-Specific Functional Neuroanatomy for Precision Psychiatry.

Authors:  Caterina Gratton; Brian T Kraus; Deanna J Greene; Evan M Gordon; Timothy O Laumann; Steven M Nelson; Nico U F Dosenbach; Steven E Petersen
Journal:  Biol Psychiatry       Date:  2019-11-07       Impact factor: 13.382

Review 8.  Personalizing neuromodulation.

Authors:  John D Medaglia; Brian Erickson; Jared Zimmerman; Apoorva Kelkar
Journal:  Int J Psychophysiol       Date:  2019-01-24       Impact factor: 2.997

9.  Impact of non-brain anatomy and coil orientation on inter- and intra-subject variability in TMS at midline.

Authors:  Erik G Lee; Priyam Rastogi; Ravi L Hadimani; David C Jiles; Joan A Camprodon
Journal:  Clin Neurophysiol       Date:  2018-07-06       Impact factor: 3.708

10.  Frequency-specific neuromodulation of local and distant connectivity in aging and episodic memory function.

Authors:  Simon W Davis; Bruce Luber; David L K Murphy; Sarah H Lisanby; Roberto Cabeza
Journal:  Hum Brain Mapp       Date:  2017-09-08       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.